Anderson L J, Tsou C, Parker R A, Chorba T L, Wulff H, Tattersall P, Mortimer P P
J Clin Microbiol. 1986 Oct;24(4):522-6. doi: 10.1128/jcm.24.4.522-526.1986.
Acute-phase serum from a patient with aplastic crisis provided sufficient human parvovirus B19 to make a monoclonal antibody against B19 and to develop antigen and immunoglobulin M (IgM) and IgG antibody detection enzyme-linked immunosorbent assays (ELISAs). The indirect capture antibody method was used for all three assays. Antigen was detected in 8 of 29 sera drawn within 2 days of onset of illness from patients with aplastic crisis. These sera had high titers of virus by electron microscopy and DNA hybridization and had no detectable B19 antibody. Antigen was not detected in serum specimens that had low titers of B19 DNA and had B19 antibody. With the IgM ELISA, we detected B19 IgM in over 85% of clinical cases of aplastic crisis and fifth disease and less than 2% of controls. The prevalence of B19 IgG antibodies increased with age. Approximately 2% of children less than 5 years of age and 49% of adults greater than 20 years of age had B19 IgG antibodies. The B19 antibody ELISAs are sensitive and specific tests to detect B19 infections.
再生障碍危象患者的急性期血清提供了足够的人细小病毒B19,用于制备抗B19单克隆抗体以及开发抗原、免疫球蛋白M(IgM)和IgG抗体检测酶联免疫吸附测定(ELISA)。所有这三种测定均采用间接捕获抗体法。在再生障碍危象患者发病后2天内采集的29份血清中,有8份检测到抗原。通过电子显微镜和DNA杂交检测,这些血清具有高滴度的病毒,且未检测到B19抗体。在B19 DNA滴度低且有B19抗体的血清标本中未检测到抗原。通过IgM ELISA,我们在超过85%的再生障碍危象和传染性红斑临床病例中检测到B19 IgM,而在对照中不到2%。B19 IgG抗体的流行率随年龄增加。小于5岁的儿童中约2%以及大于20岁的成年人中49%有B19 IgG抗体。B19抗体ELISA是检测B19感染的敏感且特异的检测方法。